Clinical Trials Logo

Lung Cancer Stage II clinical trials

View clinical trials related to Lung Cancer Stage II.

Filter by:

NCT ID: NCT06432972 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Accelerated Pulmonary Rehabilitation in the Preoperative Period

PREHAB
Start date: January 2, 2024
Phase: N/A
Study type: Interventional

This proposed project will be a single arm, non-masked study. Participants who are actively smoking with a diagnosis of COPD and new lung nodule, either confirmed or suspicious for lung cancer, with a plan for surgical resection will be recruited from the University of Vermont Medical Center (UVMMC) Lung Multidisciplinary Clinic (LMDC). All patients will be enrolled in prehab and offered smoking cessation therapy. The acceptability and feasibility of this intervention will be measured by percent enrollment in study, attendance, barriers to completion, and monitoring of adverse events. The effect of prehab will be measured by traditional metrics, including fitness, respiratory symptoms, and depression scale. Research outcomes will be measured by smoking habits, anxiety, and surgical complications. Investigators estimate that 20 participants over a two-year period will be sufficient to measure the safety and feasibility of this study. Investigators aim to enroll, on average, 2 participants per month in order to complete this study in a timely fashion. Participants will be enrolled in prehab on a rolling basis, as to not delay surgical timeline.

NCT ID: NCT06060964 Not yet recruiting - Clinical trials for Lung Cancer, Nonsmall Cell

Enabling Remote Access to Breathe Easier: A Novel Approach to Improve Symptom Management

Breathe Easier
Start date: October 2, 2023
Phase: Early Phase 1
Study type: Interventional

The goal of this clinical trial is to evaluate the preliminary affects of "Breathe Easier," an evidence-based multi-level mindfulness intervention (i.e., progressive web application) for survivors of lung cancer. The key aims of this study are to (1) Evaluate the feasibility (usability, acceptability intervention adherence) of the "Breathe Easier" and (2) assess the impact of the intervention on dyspnea, fatigue, and quality of life among survivors of lung cancer. Participants in the intervention group will use the "Breathe Easier" progressive web application for a period of 8-weeks, while participants in the control group will receive no intervention. Researchers will compare the intervention and control groups to see if there are salient differences in dyspnea, fatigue, and quality of life between the two groups.

NCT ID: NCT05281237 Recruiting - Lung Cancer Clinical Trials

Avecure Flexible Microwave Ablation Probe For Lung Nodules

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

This research study to determine the effectiveness of the AveCure Flexible Microwave Ablation Probe to destroy cancerous lung nodules up to 3 c m in size. This research study involves microwave ablation (MWA)

NCT ID: NCT05258448 Recruiting - Cardiac Disease Clinical Trials

COr Loco-regional Advanced Lung Cancer Treated With Chemo-radiotherapy (COLA)

COLA
Start date: August 2015
Phase:
Study type: Observational [Patient Registry]

Patients with loco-regional NSCLC planned for curative treatment with chemoradiotherapy will be invited to participate in a prospective study; besides routine treatment, the patients will be followed with an ECG and cardiac MR for at least two years after radiotherapy treatment.

NCT ID: NCT04991025 Recruiting - Lung Cancer Clinical Trials

Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery

Start date: October 19, 2022
Phase: Phase 2
Study type: Interventional

The purpose of the study is to explore adding the study drug certolizumab to standard chemotherapy as it may reduce the inflammation caused by the cancer and make the chemotherapy more effective in shrinking the cancer. This study will examine whether adding certolizumab to the usual treatment approach is better than, the same as, or worse than the usual approach alone.

NCT ID: NCT04970043 Not yet recruiting - Clinical trials for Lung Cancer Stage II

Camrelizumab Combined With Pemetrexed and Carboplatin for the Study of EGFR-mutated Lung Squamous NSCLC Treatment

Start date: July 31, 2021
Phase: N/A
Study type: Interventional

A single-arm, prospective, single-center, phase II, exploratory study investigating Camrelizumab combined with pemetrexed and carboplatin in the treatment of advanced non-squamous cell non-small-scale EGFR mutations (EGFR-TKI treatment failure ) Effectiveness of cell lung cancer patients

NCT ID: NCT04375566 Not yet recruiting - Clinical trials for Lung Cancer Stage II

Progressive Web App About Individualized Patient Decision Aid for NSCLC Stage I-II

Start date: October 4, 2021
Phase:
Study type: Observational

Studies indicate that the majority of early-stage non-small cell lung cancer (NSCLC) patients find it important to be involved in treatment decision making. However, in a recent study it has been reported that about 40% of the participants experienced decision conflict and feel uninformed(1). The investigators therefore developed a patient decision aid (PDA) for stage I-II NSCLC patients, that informs and empowers patients to help decide between stereotactic radiotherapy (SBRT) and surgery.

NCT ID: NCT04305613 Enrolling by invitation - Radiation Toxicity Clinical Trials

Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy

CLARITY
Start date: September 14, 2020
Phase:
Study type: Observational

This observational cohort will evaluate the cardiovascular effects of chemoradiation used to treat locally advanced, non-small cell lung cancer. Patients will be enrolled prior to the start of therapy and followed during and for at least 2 years after therapy with echocardiograms, nuclear stress tests, blood sampling, and quality of life surveys.

NCT ID: NCT04108013 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC

Start date: October 8, 2019
Phase: Phase 2
Study type: Interventional

This study is a randomized, controlled, open-label, prospective, single-center phase II clinical study. Target population is patients with stage II and IIIA resectable non-small cell lung cancer who had not received systemic chemotherapy. Study objective is to evaluate the major pathologic response of SHR-1210 + carboplatin + paclitaxel-albumin in subjects with resectable non-small cell lung cancer. SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.

NCT ID: NCT03984019 Terminated - Lung Metastases Clinical Trials

Cardiac Changes After Stereotactic Radiotherapy for Early Stage NSCLC Cancer or Lung Metastasis

HALO
Start date: January 13, 2021
Phase: N/A
Study type: Interventional

The investigators aim to optimize the radiation treatment of early stage lung cancer patients. Therefore, detailed understanding is needed of the type of toxicity and the location of these toxicities for patients who receive high fraction doses. These have not been measured in these patients before, therefore our primary research question is: is it possible to measure changes in cardiac condition after radiotherapy, with respect to cardiac arrhythmias, fibrosis, hemodynamic function change and pericarditis?